1 / 56

Infective Endocarditis

Infective Endocarditis. Matthew Leibowitz, MD David Geffen School of Medicine at UCLA Division of Infectious Diseases. Epidemiology. 10-20,000 cases per year in the US Male:Female ratio 1.7:1 New trends Mean age was 30 in 1926, now > 50% of patients are over 60

maiken
Download Presentation

Infective Endocarditis

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Infective Endocarditis Matthew Leibowitz, MD David Geffen School of Medicine at UCLA Division of Infectious Diseases

  2. Epidemiology • 10-20,000 cases per year in the US • Male:Female ratio 1.7:1 • New trends • Mean age was 30 in 1926, now > 50% of patients are over 60 • Decline in incidence of rheumatic fever • More prosthetic valves • More nosocomial cases, injected drug use • More staphylococcal infection

  3. Epidemiology • Mitral valve alone 28-45% • Aortic valve alone 5-36% (bicuspid valve in 20% of all native valve IE) • Both mitral and aortic valves 0-36% • Tricuspid valve 0-6% • Pulmonic valve <1% • Right and left sided 0-4%

  4. Classification • OLD • Subacute Bacterial Endocarditis • Death in 3-6 months • Acute Bacterial Endocarditis • Death in < 6 weeks • NEW • Native Valve Endocarditis • Prosthetic Valve Endocarditis

  5. Pathogenesis • Alteration of the valvular endothelial surface leading to deposition of platelets and fibrin • Bacteremia with seeding of non-bacterial thrombotic vegetation (NBTE) • Adherence and growth, further platelet and fibrin deposition • Extension to adjacent structures • Papillary muscle, aortic valve ring abscess, conduction system

  6. Pathogenesis • Low pressure side of structural lesion • Atrial side of mitral valve (MR) • Ventricular side of aortic valve (AR, AS with R) • Congenital abnormality (MV prolapse, bicuspid AV) • Scarring from rheumatic heart disease or sclerosis as a consequence of aging • Prosthetic valves • Other turbulence, high-velocity jets • Ventricular septal defect • Stenotic valve • Direct mechanical damage from catheters, pacemaker leads

  7. Pathogenesis • Transient bacteremia • Traumatization of mucosal surface colonized with bacteria (oral, GI) • Low grade, cleared in 15-30 minutes • Susceptibility to complement-mediated bacterial killing • Leads to concept of prophylaxis

  8. Microbiology • Staphylococcus aureus (30-40%) • Viridans group streptococci (18%) • Enterococci (11%) • Coagulase-negative staphylococci (11%) • Streptococcus bovis (7%) • Other streptococci (5%) • Non-HACEK Gram negatives (2%) • HACEK Organisms (2%) • Fungi (2%) • “Culture negative” (2-20%)

  9. Characteristics of Causative Organisms • Adherence factors critical for growth in the vegetation • Can adhere to damaged valves (Staph, Strep and Enterococci have adhesins that mediate attachment) • Staph adhesin binds fibrinogen and fibronectin • Bacteria trigger tissue-factor production from local monocytes and induce platelet aggregation so the organisms become enveloped in the vegetation • Protection from immune clearance leads to large numbers of bacteria (109-1010 per g of tissue)

  10. Risk Factors • Structural heart disease • Rheumatic, congenital, aging • Prosthetic heart valves • Injected drug use • Invasive procedures (?) • Indwelling vascular devices • Other infection with bacteremia (e.g. pneumonia, meningitis) • History of infective endocarditis

  11. Clinical Manifestations • Symptoms • Fever, sweats, chills • Anorexia, malaise, weight loss • Signs • Anemia (normochromic, normocytic) • Splenomegaly • Microscopic hematuria, proteinuria • New or changing heart murmur, CHF • Embolic or immunologic dermatologic signs • Hypergammaglobulinemia, elevated ESR, CRP, RF

  12. Cardiac Pathologic Changes • Vegetations on valve closure lines • Destruction and perforation of valve leaflet • Rupture of chordae tendinae, intraventricular septum, papillary muscles • Valve ring abscess • Myocardial abscess • Conduction abnormalities

  13. S. Aureus mitral valve vegetation, anterior leaflet

  14. Pathologic Changes • Kidney • Immune complex glomerulonephritis • Emboli with infarction, abscess • Aortic mycotic aneurysms • Cerebral embolism • Infarction, abscess, mycotic aneurysms • Purulent meningitis is rare

  15. Pathologic Changes • Splenic enlargement, infarction • Septic or bland pulmonary embolism • Skin • Petechiae • Osler nodes: diffuse infiltrate of neutrophils, and monocytes in the dermal vessels with immune complex deposition. Tender and erythematous • Janeway lesions: septic emboli with bacteria, neutrophils and SQ hemorrhage and necrosis. Blanching and non-tender. Palms and soles

  16. Case Definition • 1977 Pelletier and Petersdorf criteria • 1981 von Reyn criteria • 1994 Duke criteria • 2000 Modified Duke criteria

  17. Modified Duke Criteria • Major Criteria • Positive blood cultures with typical organisms • Persistently positive blood cultures • Evidence of Endocardial involvement • Positive Echocardiogram • Oscillating intracardiac mass • Abscess • Dehiscence of prosthetic valve • New Valvular regurgitation

  18. Modified Duke Criteria • Minor Criteria • Predisposition (valvular disease or IDU) • Fever • Vascular phenomena (Arterial emboli, septic pulmonary infarcts, intracranial hemorrhage, Osler, Janeway) • Immunologic phenomena (GN, Osler, Roth spots, Rheumatoid Factor)

  19. Modified Duke Criteria • Definite IE • Pathologic criteria • Clinical criteria • 2 Major Criteria OR • 1 Major and 3 minor Criteria OR • 5 Minor Criteria • Possible IE • 1 Major and 1 Minor OR • 3 Minor • Rejected IE

  20. Blood Cultures • MULTIPLE BLOOD CULTURES BEFORE EMPIRIC THERAPY • If not critically ill • 3 blood cultures over 12-24 hour period • ? Delay therapy until diagnosis confirmed • If critically ill • 3 blood cultures over one hour • No more than 2 from same venipuncture • Relatively constant bacteremia

  21. “Culture Negative” IE • Less common with improved blood culture methods • Special media required • Brucella, Mycoplasma, Chlamydia, Histoplasma, Legionella, Bartonella • Longer incubation may be required • HACEK • Coxiella burnetii (Q Fever), Trophyrema whipplei will not grow in cell-free media

  22. HACEK • Haemophilus aphrophilus, H. paraphrophilus, parainfluenzae • Actinobacillus actinomycetemcomitans • Cardiobacterium hominis • Eikenella corrodens • Kingella kingae

  23. Other microbiologic methods • PCR • Coxiella burnetii • Tropheryma whipplei • Bartonella henselae • Serology • Coxiella burnetii • Bartonella • Brucella • Legionella • Chlamydophila psittaci

  24. Echocardiography • Transthoracic • Relatively low sensitivity • Good specificity • Transesophageal • Detection of valve ring abscess (87% vs. 28% sensitivity for TTE) • Detection of prosthetic valve IE

  25. When to go to TEE first? • Limited thoracic windows = TTE low sensitivity • Prosthetic valves • Prior valvular abnormality • S. aureus bacteremia and suspected IE • Bacteremia with organisms likely to cause IE = high prior probability of IE

  26. Other tests • Electrocardiogram • Conduction delays • Ischemia or infarction • Chest X-ray • Septic emboli in right-sided IE • Valve calcification • CHF

  27. Treatment of IE • Native vs. Prosthetic Valve • Bactericidal therapy is necessary • Eradication of bacteria in the vegetation • May be metabolically inactive (stationary phase) • May need higher concentrations of antimicrobial agents

  28. Antimicrobial Therapy • Most patients are afebrile in 3-5 days • Long duration of therapy (4-6 weeks or more) • Combination therapy most important for • Shorter course regimens • Enterococcal endocarditis • Prosthetic valve infections

  29. Native Valve IE • Viridans Streptococci and S. bovis • Aqueous Penicillin G 12-20 million units/day continuously or divided q4 or q6 for 4 weeks • If intermediate susceptibility to penicillin, aqueous penicillin G 24 million units or ceftriaxone 2 g q24 PLUS aminoglycoside for the first 2 weeks

  30. Native Valve IE • Aminoglycosides for synergy • Low concentrations are adequate (1-3 mcg/ml) • Gentamicin 3 mg/kg divided q12 or q8 • Little data for q24 dosing

  31. Native Valve IE • Enterococci, ampicillin sensitive • High rates of failure • β-lactams are bacteriostatic, must combine with aminoglycoside for optimal therapy • High-level gentamicin resistance occurs in 35% • High-dose ampicillin for 8-12 weeks • Enterococci, ampicillin resistant • Vancomycin plus gentamicin • Enterococci, vancomycin resistant • Linezolid or daptomycin • Penicillin + vancomycin + gentamicin ?

  32. Native Valve IE • S. aureus • Penicillinase-resistant semi-synthetic penicillin (oxacillin or nafcillin) 1.5-2 g IV q4 or cephalosporin (cefazolin 1-2 g IV q8) for 4-6 weeks • Aminoglycoside synergistic but does not affect survival, not recommended • Short course in right-sided IE • 2 weeks of semi-synthetic penicillin and aminoglycoside

  33. Native Valve IE • Methicillin-resistant S. aureus • Vancomycin is bacteriostatic • Vancomycin plus aminoglycoside or rifampin • Daptomycin • Linezolid

  34. Native Valve IE • HACEK • Ceftriaxone 2 g IV q 24 x 4-6 weeks • Fungal • Amphotericin • Fluconazole • Caspofungin, little data • Surgery usually necessary 1-2 weeks into treatment

  35. Native Valve IE • Indications for surgery • Refractory CHF • More than one systemic embolic event • Uncontrolled infection • Physiologically significant valvular dysfunction • Ineffective antimicrobial therapy (e.g. fungal) • Local suppurative complications • Mycotic aneurysm

  36. Prosthetic Valve IE • Staphylococci most common • Coagulase negative staphylococci • Enterococcus • Nutritonally variant streptococci • Fungi

  37. Prosthetic Valve IE • Risk is greatest in the first 3 months and first year (early PV IE) • Coagulase-negative staphylococci in early endocarditis, S. aureus • Late-onset more similar to native valve disease in microbiology but more coagulase-negative staphylococci. Valve is endothelialized

  38. Prosthetic Valve IE • TEE should be used first • Staphylococci • Vancomycin or oxacillin plus rifampin for at least six weeks, gentamicin for the first two weeks (3 mg/kg q24) • Rifampin started at least 2 days after 2 other agents to avoid resistance

  39. Prophylaxis of IE • Uncertainty and controversy • No randomized trials • Indirect evidence (uncontrolled clinical series, case-control studies) • Decision analysis

More Related